Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide in IBS-C
NCT03573908Phase 3Completed
- Sponsor
- Ironwood Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Linaclotide 290 µg with Placebo (2 arms). Primary endpoint: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) at 12 weeks. Started Jun 2018; status: completed.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT03573908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573908.